Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

Amgen scores with new thyroid eye disease formulation

 April 7, 2026

Pharmaphorum

Can Amgen’s subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?

Clinical DataOphthalmologyRead full story

Post navigation

FDA floats new clinical trial reforms; Takeda punts Denali brain drug →
← Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com